News

The Boston-based biotech company will use an inventory of patient-derived cancer cells to develop new lab-grown tumor models to accelerate and refine oncology research, and provide more targeted treatments for cancer patients. [For immediate release: Ashland, MA and San Antonio,... Read More

Register now for a webinar on medical devices with expert panelists discussing current accepted methods and future outlooks.

MatTek CEO Alex Armento and Visikol CEO Dr. Michael Johnson, announced a commercial integration under the MatTek name.